Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 37 peer-reviewed journal articles Updated
Endocrinology

The Genetics of MODY: Subtypes and How They Behave

At a Glance

MODY is a group of genetic conditions caused by a single gene mutation, inherited in an autosomal dominant pattern. The specific mutated gene (such as GCK, HNF1A, HNF4A, or HNF1B) determines the disease's behavior, affected organs, and whether treatment requires insulin, oral medications, or none at all.

MODY is not a single disease, but a group of different conditions caused by a mutation in a single gene [1][2]. Because each gene plays a different role in the body, the “subtype” of MODY you have determines everything from your treatment plan to whether you need to worry about other organs, like your kidneys or liver [3][4].

How MODY is Passed Down

MODY follows a pattern called autosomal dominant inheritance [1][5].

  • Autosomal: The gene is not on a sex chromosome, so it affects men and women equally.
  • Dominant: You only need one copy of the mutated gene (from one parent) to have the condition [1][6].

If a parent has MODY, there is a 50% chance that each child will inherit the mutation [1][7]. A genetic counselor can provide guidance on how to share this information with relatives safely and constructively [8]. However, not everyone who inherits the gene will develop symptoms at the same age or with the same severity—a concept doctors call variable penetrance [9][10].

The Four Major Subtypes

While there are over 14 known types of MODY, the vast majority of cases fall into one of these four categories:

1. GCK-MODY (MODY2): The “Broken Thermostat”

The GCK gene provides instructions for making glucokinase, an enzyme that acts as your body’s “glucose sensor” or thermostat [11][12].

  • Mechanism: In a person without MODY, the pancreas “kicks on” and releases insulin when blood sugar hits a certain level. In GCK-MODY, this thermostat is set a bit too high [13][14].
  • Behavior: Your blood sugar stays slightly elevated (mild fasting hyperglycemia) from birth, but it is stable and usually does not get worse over time [15][16].
  • Treatment: Most people with this subtype do not require any medication and have a very low risk of typical diabetes complications [16][17].

2. HNF1A-MODY (MODY3): The Sensitive Subtype

This is the most common form of MODY. The HNF1A gene helps regulate how the pancreas responds to glucose and how much insulin it releases [18][19].

  • Mechanism: Over time, the pancreas loses its ability to produce enough insulin, leading to a progressive rise in blood sugar [20][21].
  • Behavior: It often presents in the teens or early twenties. A unique feature is that people with this subtype are often extremely sensitive to sulfonylureas (oral diabetes pills) [22][23].
  • Extrapancreatic Features: It can sometimes be associated with benign liver tumors called hepatic adenomas [24]. These are usually rare and do not typically require routine screening unless you have symptoms or take certain medications like oral contraceptives [25].

3. HNF4A-MODY (MODY1): The Birth Weight Subtype

This subtype is very similar to HNF1A-MODY but has a unique footprint in early life [21][26].

  • Mechanism: Like HNF1A, this gene affects insulin secretion and progresses over time [20].
  • Behavior: A key clue for this subtype is neonatal macrosomia—being born with a high birth weight (over 9 lbs / 4kg)—or having low blood sugar (hypoglycemia) as a newborn [21][26].
  • Treatment: Like HNF1A, many patients respond very well to oral sulfonylureas instead of insulin [22][27].

4. HNF1B-MODY (MODY5): The Multi-System Subtype

Unlike other forms of MODY that mostly affect the pancreas, HNF1B is essential for the development of many organs, including the kidneys and reproductive system [28][29].

  • Mechanism: This gene mutation often causes the pancreas to be smaller than normal or even partially missing [28][30].
  • Extrapancreatic Manifestations: The most common sign is renal cysts (fluid-filled sacs in the kidneys) [31][32]. It can also cause:
    • Structural abnormalities in the uterus or vagina [33][34].
    • Low blood magnesium levels (hypomagnesemia) [35][36].
    • Gout at a young age [30].
  • Treatment: This subtype often requires insulin treatment because the pancreas itself may be underdeveloped [4][37].
Subtype Gene Primary Effect Common Treatment
MODY2 GCK Higher glucose “set-point” Usually none
MODY3 HNF1A Low insulin secretion over time Sulfonylureas
MODY1 HNF4A Large birth weight; low insulin Sulfonylureas
MODY5 HNF1B Kidney cysts; small pancreas Insulin

Previous: What is MODY? | Return to Home | Next: Testing for MODY

Common questions in this guide

How is MODY passed down in families?
MODY follows an autosomal dominant inheritance pattern. This means you only need to inherit the mutated gene from one parent to have the condition. If a parent has MODY, there is a 50% chance that each child will inherit the mutation.
What is the treatment for GCK-MODY (MODY2)?
GCK-MODY acts like a slightly altered glucose thermostat, keeping blood sugar mildly elevated but stable from birth. Most people with this subtype do not require any diabetes medication and have a very low risk of developing typical diabetes complications.
Why is HNF1B-MODY (MODY5) considered a multi-system condition?
While most forms of MODY primarily affect the pancreas, HNF1B-MODY can affect multiple organs. It commonly causes fluid-filled cysts in the kidneys, low magnesium levels, and reproductive tract abnormalities. Because it can cause an underdeveloped pancreas, it often requires insulin therapy.
Can oral diabetes pills be used to treat MODY?
Yes, depending on your subtype. People with HNF1A-MODY (MODY3) and HNF4A-MODY (MODY1) are typically very sensitive to a class of oral diabetes pills called sulfonylureas. For these patients, these pills are often highly effective and can be used instead of insulin.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my family history and lab work, which MODY gene mutation do you think is most likely?
  2. 2.Are there any specific risks for complications, like kidney issues or liver adenomas, associated with my subtype?
  3. 3.Should I have a renal ultrasound or a magnesium blood test to check for signs of HNF1B-MODY?
  4. 4.Does my fasting blood sugar level look like the stable, mild elevation typically seen in GCK-MODY?
  5. 5.Can you refer me to a genetic counselor to help my family navigate the testing process?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (37)
  1. 1

    Next generation sequencing targeted gene panel in Greek MODY patients increases diagnostic accuracy.

    Tatsi EB, Kanaka-Gantenbein C, Scorilas A, et al.

    Pediatric diabetes 2020; (21(1)):28-39 doi:10.1111/pedi.12931.

    PMID: 31604004
  2. 2

    A novel nonsense mutation c.747C>G in the NEUROD1 gene detected within a Chinese family affected by maturity-onset diabetes of the young type 6.

    Li Y, Wen Q, Shao H, et al.

    Journal of diabetes 2024; (16(9)):e13607 doi:10.1111/1753-0407.13607.

    PMID: 39264012
  3. 3

    Treatment Options for MODY Patients: A Systematic Review of Literature.

    Delvecchio M, Pastore C, Giordano P

    Diabetes therapy : research, treatment and education of diabetes and related disorders 2020; (11(8)):1667-1685 doi:10.1007/s13300-020-00864-4.

    PMID: 32583173
  4. 4

    Case Report: A case of HNF1B mutation patient with first presentation of diabetic ketosis.

    Ge S, Yang M, Gong W, et al.

    Frontiers in endocrinology 2022; (13()):917819 doi:10.3389/fendo.2022.917819.

    PMID: 35992134
  5. 5

    Comprehensive genetic screening: The prevalence of maturity-onset diabetes of the young gene variants in a population-based childhood diabetes cohort.

    Johnson SR, Ellis JJ, Leo PJ, et al.

    Pediatric diabetes 2019; (20(1)):57-64 doi:10.1111/pedi.12766.

    PMID: 30191644
  6. 6

    C.487C>T mutation in PAX4 gene causes MODY9: A case report and literature review.

    Zhang D, Chen C, Yang W, et al.

    Medicine 2022; (101(51)):e32461 doi:10.1097/MD.0000000000032461.

    PMID: 36595822
  7. 7

    Frequency and characterization of mutations in genes in a large cohort of patients referred to MODY registry.

    Breidbart E, Deng L, Lanzano P, et al.

    Journal of pediatric endocrinology & metabolism : JPEM 2021; (34(5)):633-638 doi:10.1515/jpem-2020-0501.

    PMID: 33852230
  8. 8

    Monogenic Diabetes Accounts for 6.3% of Cases Referred to 15 Italian Pediatric Diabetes Centers During 2007 to 2012.

    Delvecchio M, Mozzillo E, Salzano G, et al.

    The Journal of clinical endocrinology and metabolism 2017; (102(6)):1826-1834 doi:10.1210/jc.2016-2490.

    PMID: 28323911
  9. 9

    Maturity-onset Diabetes of the Young Type 7 (MODY7) and the Krüppellike Factor 11 Mutation (KLF11). A Review.

    Mancera-Rincón P, Luna-España MC, Rincon O, et al.

    Current diabetes reviews 2024; (20(1)):e210323214817 doi:10.2174/1573399819666230321114456.

    PMID: 36944622
  10. 10

    Why all MODY variants in transcription factor genes are dominantly inherited.

    Zug R

    Frontiers in genetics 2025; (16()):1690468 doi:10.3389/fgene.2025.1690468.

    PMID: 41356216
  11. 11

    A clinical mutation in glucokinase causing maturity-onset diabetes in the young type 2 increases enzyme activity.

    Aránguiz O, Rivera R, Durruty P, et al.

    FEBS letters 2023; (597(11)):1469-1478 doi:10.1002/1873-3468.14561.

    PMID: 36520489
  12. 12

    Additive Effects of Dorzagliatin and Glucagon-Like Peptide 1 Receptor Agonism in a Novel Mouse Model of GCK-MODY and in Obese db/db Mice.

    Salazar S, Delgadillo-Silva LF, Carapeto P, et al.

    Diabetes 2026; (75(1)):99-114 doi:10.2337/db25-0520.

    PMID: 41196662
  13. 13

    Diagnosis and management of glucokinase monogenic diabetes in pregnancy: current perspectives.

    Rudland VL

    Diabetes, metabolic syndrome and obesity : targets and therapy 2019; (12()):1081-1089 doi:10.2147/DMSO.S186610.

    PMID: 31372018
  14. 14

    Dorzagliatin, a Dual-Acting Glucokinase Activator, Increases Insulin Secretion and Glucose Sensitivity in Glucokinase Maturity-Onset Diabetes of the Young and Recent-Onset Type 2 Diabetes.

    Chow E, Wang K, Lim CKP, et al.

    Diabetes 2023; (72(2)):299-308 doi:10.2337/db22-0708.

    PMID: 36342518
  15. 15

    Recognition and Management of Individuals With Hyperglycemia Because of a Heterozygous Glucokinase Mutation.

    Chakera AJ, Steele AM, Gloyn AL, et al.

    Diabetes care 2015; (38(7)):1383-92 doi:10.2337/dc14-2769.

    PMID: 26106223
  16. 16

    Mutations in GCK May Lead to MODY2 by Reducing Glycogen Synthesis.

    Li Z, Li K, Sun Y, et al.

    Advanced biology 2022; (6(11)):e2200097 doi:10.1002/adbi.202200097.

    PMID: 35770790
  17. 17

    Generation and characterization of an induced pluripotent stem cell (iPSC) line SDQLCHi063-A from peripheral blood mononuclear cells of a patient with Maturity-onset diabetes of the young type 2 carrying GCK exon 1 deletion.

    Gao M, Li X, Lv Y, et al.

    Stem cell research 2024; (77()):103389 doi:10.1016/j.scr.2024.103389.

    PMID: 38507882
  18. 18

    Decreased GLUT2 and glucose uptake contribute to insulin secretion defects in MODY3/HNF1A hiPSC-derived mutant β cells.

    Low BSJ, Lim CS, Ding SSL, et al.

    Nature communications 2021; (12(1)):3133 doi:10.1038/s41467-021-22843-4.

    PMID: 34035238
  19. 19

    Reduced calcium levels and accumulation of abnormal insulin granules in stem cell models of HNF1A deficiency.

    González BJ, Zhao H, Niu J, et al.

    Communications biology 2022; (5(1)):779 doi:10.1038/s42003-022-03696-z.

    PMID: 35918471
  20. 20

    Maturity-Onset Diabetes of the Young: Rapid Evidence Review.

    Kant R, Davis A, Verma V

    American family physician 2022; (105(2)):162-167.

    PMID: 35166506
  21. 21

    In silico and in vitro analyses of the pathological relevance of the R258H mutation of hepatocyte nuclear factor 4α identified in maturity-onset diabetes of the young type 1.

    Sugawara K, Nomura K, Okada Y, et al.

    Journal of diabetes investigation 2019; (10(3)):680-684 doi:10.1111/jdi.12960.

    PMID: 30325586
  22. 22

    Genetic causes and treatment of neonatal diabetes and early childhood diabetes.

    Barbetti F, D'Annunzio G

    Best practice & research. Clinical endocrinology & metabolism 2018; (32(4)):575-591 doi:10.1016/j.beem.2018.06.008.

    PMID: 30086875
  23. 23

    The use of SGLT2 inhibitors in achieving glycaemic control in maturity-onset diabetes of the young type 3.

    Sriravindrarajah A, Fernandes A, Wu T, Hocking S

    Endocrinology, diabetes & metabolism case reports 2021; (2021()).

    PMID: 34866061
  24. 24

    Liver adenomatosis in patients with hepatocyte nuclear factor-1 alpha maturity onset diabetes of the young (HNF1A-MODY): Clinical, radiological and pathological characteristics in a French series.

    Haddouche A, Bellanne-Chantelot C, Rod A, et al.

    Journal of diabetes 2020; (12(1)):48-57 doi:10.1111/1753-0407.12959.

    PMID: 31166087
  25. 25

    [Hepatocyte nuclear factor 1α-inactivated hepatocellular adenomatosis in a patient with maturity-onset diabetes of the young type 3: case report and literature review].

    Hirata E, Shimizu S, Umeda S, et al.

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 2015; (112(9)):1696-704 doi:10.11405/nisshoshi.112.1696.

    PMID: 26346360
  26. 26

    Monogenic diabetes: a gateway to precision medicine in diabetes.

    Zhang H, Colclough K, Gloyn AL, Pollin TI

    The Journal of clinical investigation 2021; (131(3)).

    PMID: 33529164
  27. 27

    Case Report: Identification of a HNF1A exons 1-10 heterozygous deletion in a Chinese MODY family.

    Lei M, Xue M, Wang H, et al.

    Frontiers in endocrinology 2026; (17()):1743021 doi:10.3389/fendo.2026.1743021.

    PMID: 41778156
  28. 28

    Maturity-onset diabetes of the young type 5 a MULTISYSTEMIC disease: a CASE report of a novel mutation in the HNF1B gene and literature review.

    Mateus JC, Rivera C, O'Meara M, et al.

    Clinical diabetes and endocrinology 2020; (6()):16 doi:10.1186/s40842-020-00103-6.

    PMID: 32864159
  29. 29

    Insights into the etiology and physiopathology of MODY5/HNF1B pancreatic phenotype with a mouse model of the human disease.

    Quilichini E, Fabre M, Nord C, et al.

    The Journal of pathology 2021; (254(1)):31-45 doi:10.1002/path.5629.

    PMID: 33527355
  30. 30

    Frequency and Characteristics of MODY 1 (HNF4A Mutation) and MODY 5 (HNF1B Mutation): Analysis From the DPV Database.

    Warncke K, Kummer S, Raile K, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(3)):845-855 doi:10.1210/jc.2018-01696.

    PMID: 30535056
  31. 31

    [Clinical phenotypes of hepatocyte nuclear factor 1 homeobox b-associated disease].

    Wang F, Yao Y, Yang HX, et al.

    Zhonghua er ke za zhi = Chinese journal of pediatrics 2017; (55(9)):658-662 doi:10.3760/cma.j.issn.0578-1310.2017.09.006.

    PMID: 28881510
  32. 32

    Reverse Phenotyping Maternal Cystic Kidney Disease by Diagnosis in a Newborn: Case Report and Literature Review on Neonatal Cystic Kidney Diseases.

    Ruzgienė D, Sutkevičiūtė M, Burnytė B, et al.

    Acta medica Lituanic 2021; (28(2)):308-316 doi:10.15388/Amed.2021.28.2.5.

    PMID: 35474932
  33. 33

    17q12 Deletion Syndrome as a Rare Cause for Diabetes Mellitus Type MODY5.

    Roehlen N, Hilger H, Stock F, et al.

    The Journal of clinical endocrinology and metabolism 2018; (103(10)):3601-3610 doi:10.1210/jc.2018-00955.

    PMID: 30032214
  34. 34

    Unusual manifestations of young woman with MODY5 based on 17q12 recurrent deletion syndrome.

    Cheng Y, Zhong DP, Ren L, et al.

    BMC endocrine disorders 2022; (22(1)):77 doi:10.1186/s12902-022-00989-6.

    PMID: 35346144
  35. 35

    A Case of Diabetes Mellitus Type MODY5 as a Feature of 17q12 Deletion Syndrome

    Yaşar Köstek H, Özgüç Çömlek F, Gürkan H, et al.

    Journal of clinical research in pediatric endocrinology 2024; (16(2)):205-210 doi:10.4274/jcrpe.galenos.2022.2022-3-2.

    PMID: 36511482
  36. 36

    The Clinical Characteristics and Gene Mutations of Maturity-Onset Diabetes of the Young Type 5 in Sixty-One Patients.

    Ge S, Yang M, Cui Y, et al.

    Frontiers in endocrinology 2022; (13()):911526 doi:10.3389/fendo.2022.911526.

    PMID: 35846334
  37. 37

    Challenges in the management of patients with HNF1B MODY and multisystem manifestations: the cases of two adolescent boys.

    Vourdoumpa A, Paltoglou G, Mertzanian A, et al.

    Hormones (Athens, Greece) 2024; (23(3)):439-445 doi:10.1007/s42000-024-00580-9.

    PMID: 38980656

This page explains the genetics and subtypes of MODY for educational purposes only. Always consult a genetic counselor or endocrinologist to interpret your genetic testing results and determine your treatment plan.

Get notified when new evidence is published on MODY.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.